CRISPR CEO Samarth Kulkarni and Vertex CEO Reshma Kewalramani
Vertex ponies up $100M for CRISPR's gene editing tech to develop new diabetes modality
Vertex is paying nine figures to get its hands on CRISPR Therapeutics’ gene editing technology in a bid to make a third approach for type …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
